ATC Group: J07BK Varicella zoster vaccines

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07BK in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines
4 J07BK Varicella zoster vaccines

Group J07BK contents

Code Title
J07BK01 Varicella, live attenuated
J07BK02 Zoster, live attenuated
J07BK03

Active ingredients in J07BK

Active Ingredient

Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.

Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications.

Related product monographs

Document Type Information Source  
 SHINGRIX Powder for suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 VARILRIX Powder and solvent for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ZOSTAVAX Powder and solvent for suspension for injection MPI, EU: SmPC European Medicines Agency (EU)